444 Bio-IR or csDMARD-IR #PsA pts were Rx w/ anti-IL-23, risankizumab 150 mg Sc vs PBO at Wks 0, 4, 16, @wk 24 RIZ had significantly better ACR20 resp (51% vs 26%, p<0.001). No differences in SAE (4 vs 5.5%) or SIE (0.9% vs 2.3%). https://t.co/os2AMgG4kc